Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2005

01-08-2005

DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors

Authors: Moritz N. Wente, Jörg Kleeff, Markus W. Büchler, Jantien Wanders, Peter Cheverton, Stephen Langman, Helmut Friess

Published in: Investigational New Drugs | Issue 4/2005

Login to get access
Metadata
Title
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors
Authors
Moritz N. Wente
Jörg Kleeff
Markus W. Büchler
Jantien Wanders
Peter Cheverton
Stephen Langman
Helmut Friess
Publication date
01-08-2005
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2005
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-005-1442-2

Other articles of this Issue 4/2005

Investigational New Drugs 4/2005 Go to the issue

Erratum

Phase I Study of Tomudex and Doxorubicin in Patients with Locally Advanced, Inoperable or Metastatic Cancer (IND.98)

OriginalPaper

Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP

OriginalPaper

Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study

OriginalPaper

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

OriginalPaper

BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)

OriginalPaper

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits